Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02256969 · ClinicalTrials.gov registry record · Phase 4
Intraductal Meibomian Gland Probing Trial
A Phase 4 study, sponsored by Joseph B. Ciolino, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT02256969 is a Phase 4 study that has completed, run by Joseph B. Ciolino, MD. The registered enrollment target is 45 participants.
The verdict
NCT02256969, a Phase 4 study, has completed, sponsored by Joseph B. Ciolino, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or their symptoms. The investigators are also evaluating the effects of using two (2) post-procedural medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after the MGP procedure has an effect on its outcome.
Interventions
- DRUG Blephamide
- DRUG GenTeal PM Night-Time
- PROCEDURE Meibomian Gland Probing
- PROCEDURE Sham Meibomian Gland Probing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02256969
The ClinicalTrials.gov registry entry for NCT02256969 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph B. Ciolino, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Blephamide is the first listed.
NCT02256969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02256969 about?
NCT02256969 is a clinical study titled "Intraductal Meibomian Gland Probing Trial". In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or t...
What is the current status of trial NCT02256969?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2014-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02256969?
The interventions under investigation include: Blephamide (DRUG), GenTeal PM Night-Time (DRUG), Meibomian Gland Probing (PROCEDURE), Sham Meibomian Gland Probing (PROCEDURE).
Who is sponsoring clinical trial NCT02256969?
This trial is sponsored by Joseph B. Ciolino, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.